EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry

Kenneth I Berger, Yin-Hsiu Chien, Alberto Dubrovsky, Priya S Kishnani, Juan C Llerena, Edward Neilan, Mark Roberts, Bun Sheng, Julie L Batista, Magali Periquet, Kathryn M Wilson, Ans T van der Ploeg

Journal of Neurology · 2024

DOI: 10.1007/s00415-024-12489-9 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Neurology, 2024. Verfasst von Kenneth I Berger und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Critical Care and Sleep Medicine, NYU Grossman School of Medicine, and the André Cournand Pulmonary Physiology Laboratory, Bel…. Hauptthemen laut MEDLINE: alpha-Glucosidases, Glycogen Storage Disease Type II, Registries. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic respiratory insufficiency from progressive muscle weakness causes morbidity and mortality in late-onset Pompe disease (LOPD). Previous Pompe Registry (NCT00231400) analyses for ≤ 5 years’ alglucosidase alfa treatment showed a single linear time trend of stable forced vital capacity (FVC) % predicted.

Methods

To assess longer term Pompe Registry data, piecewise linear mixed model regression analyses estimated FVC% predicted trajectories in invasive-ventilator-free patients with LOPD aged ≥ 5 years. We estimated annual FVC change 0–6 months, > 6 months–5 years, and > 5–13 years from treatment initiation, adjusting for baseline age, sex, and non-invasive ventilation.

Findings

Among 485 patients (4612 FVC measurements; 8.3 years median follow-up), median ages at symptom onset, diagnosis, and alglucosidase alfa initiation were 34.3, 41.1, and 44.9 years, respectively. FVC% increased during the first 6 months’ treatment (slope 1.83%/year; 95% confidence interval: 0.66, 3.01; P = 0.0023), then modestly declined −0.54%/year (−0.79, −0.30; P < 0.0001) during > 6 months–5 years, and −1.00%/year (−1.36, −0.63; P < 0.0001) during > 5–13 years. The latter two periods’ slopes were not significantly different from each other ( P difference = 0.0654) and were less steep than published natural history slopes (−1% to −4.6%/year). Estimated individual slopes were ≥ 0%/year in 96.1%, 30.3%, and 13.2% of patients during the 0–6 month, > 6 month–5 year, and > 5–13 year periods, respectively.

Conclusion

These real-world data indicate an alglucosidase alfa benefit on FVC trajectory that persists at least 13 years compared with published natural history data. Nevertheless, unmet need remains since most individuals demonstrate lung function decline 5 years after initiating treatment. Whether altered FVC trajectory impacts respiratory failure incidence remains undetermined.

Trial registration

This study was registered (NCT00231400) on ClinicalTrials.gov on September 30, 2005, retrospectively registered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha-GlucosidasesGlycogen Storage Disease Type IIRegistriesAdolescentAdultChildChild, PreschoolFemaleHumansMaleMiddle AgedYoung AdultEnzyme Replacement TherapyFollow-Up StudiesVital Capacity

Stichwörter der Autor:innen

Alglucosidase alfaForced vital capacityLate-onset Pompe diseaseObservational studyPompe RegistryReal-world evidence

Substanzen

alpha-GlucosidasesGAA protein, human

Autor:innen und Institutionen

  • Division of Pulmonary, Critical Care and Sleep Medicine, NYU Grossman School of Medicine, and the André Cournand Pulmonary Physiology Laboratory, Bellevue Hospital, New York, NY, USA. kenneth.berger43@gmail.com.
  • Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Neurology, Neuromuscular Disease Unit, Institute of Neuroscience, Favaloro Foundation, Buenos Aires, Argentina.
  • Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC, USA.
  • Centro de Genética Médica, Instituto Fernandes Figueira/FIOCRUZ, Rio de Janeiro, Brazil.
  • National Organization for Rare Disorders (NORD®), Quincy, MA, USA.

Förderung

  • Sanofi

Zitieren

APA

Berger, K. I., Chien, Y. H., Dubrovsky, A., Kishnani, P. S., Llerena, J. C., Neilan, E., Roberts, M., Sheng, B., Batista, J. L., Periquet, M., Wilson, K. M., & van der Ploeg, A. T. (2024). Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry. Journal of Neurology. https://doi.org/10.1007/s00415-024-12489-9

Vancouver

Berger KI, Chien YH, Dubrovsky A, Kishnani PS, Llerena JC, Neilan E, et al. Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry. Journal of Neurology. 2024. doi:10.1007/s00415-024-12489-9

BibTeX
@article{Berger2024,
  author = {Berger, Kenneth I and Chien, Yin-Hsiu and Dubrovsky, Alberto and Kishnani, Priya S and Llerena, Juan C and Neilan, Edward and Roberts, Mark and Sheng, Bun and Batista, Julie L and Periquet, Magali and Wilson, Kathryn M and van der Ploeg, Ans T},
  title = {Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry},
  journal = {Journal of Neurology},
  year = {2024},
  doi = {10.1007/s00415-024-12489-9}
}
Kostenlos starten →